A 48-year-old female from Mumbai with a history of TB treatment 2 years ago (completed 6-month RIPE regimen) now presents with recurrent cough and fever for 2 months. Sputum smear is positive. Gene Xpert MTB/RIF shows *M. tuberculosis* with rifampicin AND isoniazid resistance. Subsequent drug susceptibility testing (DST) reveals additional resistance to fluoroquinolones and second-line injectable agents (amikacin, capreomycin). She is HIV-negative and has normal renal function. What is the most likely diagnosis, and what is the recommended first-line treatment for this condition?

Explanation

## Diagnosis: XDR-TB ### Definition and Classification **XDR-TB (Extensively Drug-Resistant TB)** is defined as TB with resistance to: 1. **Isoniazid AND rifampicin** (i.e., MDR-TB) PLUS 2. **Any fluoroquinolone** (levofloxacin, moxifloxacin) PLUS 3. **At least one second-line injectable agent** (amikacin, kanamycin, capreomycin) **High-Yield:** This patient meets all three criteria: - INH + RIF resistance ✓ - Fluoroquinolone resistance (levofloxacin/moxifloxacin) ✓ - Injectable resistance (amikacin, capreomycin) ✓ ### Comparison: MDR-TB vs. XDR-TB | Feature | MDR-TB | XDR-TB | |---------|--------|--------| | **Resistance Profile** | INH + RIF | INH + RIF + FQ + Injectable | | **Treatment Duration** | 20 months | 20 months | | **Core Drugs** | Bedaquiline, FQ, linezolid, PZA | Bedaquiline, linezolid, newer agents | | **Newer Agents** | Optional | **Mandatory** (delamanid or pretomanid) | | **Cure Rate** | ~60–70% | ~40–50% | | **Mortality** | 10–15% | 20–30% | ### Recommended XDR-TB Regimen (WHO 2023) ```mermaid flowchart TD A[XDR-TB Confirmed]:::outcome --> B[Bedaquiline]:::action A --> C[Linezolid]:::action A --> D[Newer Agent: Delamanid OR Pretomanid]:::action A --> E[Pyrazinamide]:::action B --> F[20-month course]:::outcome C --> F D --> F E --> F ``` **Key Point:** - **Bedaquiline** (ATP synthase inhibitor) is essential in XDR-TB. - **Linezolid** (oxazolidinone) provides excellent lung penetration and is bactericidal. - **Delamanid** (benzothiazinone) or **Pretomanid** (nitroimidazole) are newer agents with activity against XDR-TB and are now WHO-recommended as part of the core regimen. - **Fluoroquinolones are contraindicated** in this patient because of documented resistance. **Clinical Pearl:** XDR-TB is a public health emergency with significantly worse outcomes than MDR-TB. Early diagnosis and initiation of appropriate therapy are critical. Newer agents (delamanid, pretomanid) have improved cure rates in XDR-TB from ~20% (with older regimens) to ~40–50%. ## Why This Answer The patient has documented resistance to: - First-line agents (INH, RIF) - Fluoroquinolones (levofloxacin) - Second-line injectables (amikacin, capreomycin) This is the definition of XDR-TB. The standard regimen must include bedaquiline, linezolid, and a newer agent (delamanid or pretomanid) because fluoroquinolones and injectables are no longer viable options.